Humacyte Inc
(NASDAQ:HUMA)
$2.88
-0.05[-1.71%]
Last update: 4:00PM (Delayed 15-Minutes)
Get Real Time Here
$3.03
0.1500[5.21%]
Open2.940Close2.880
Vol / Avg.355.938K / 709.414KMkt Cap297.891M
Day Range2.875 - 2.97552 Wk Range1.960 - 5.600

Humacyte Stock (NASDAQ:HUMA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Outperform

Highest Price Target1

$17.00

Lowest Price Target1

$7.00

Consensus Price Target1

$13.83

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
42000

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Benchmark
  • BTIG
  • Cowen & Co.
  • Oppenheimer

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Humacyte

All Ratings (12)

Upgrades (0)

Downgrades (0)

Initiations (5)

Q

What is the target price for Humacyte (HUMA)?

A

The latest price target for Humacyte (NASDAQ: HUMA) was reported by Cantor Fitzgerald on September 21, 2023. The analyst firm set a price target for $7.00 expecting HUMA to rise to within 12 months (a possible 143.06% upside). 7 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Humacyte (HUMA)?

A

The latest analyst rating for Humacyte (NASDAQ: HUMA) was provided by Cantor Fitzgerald, and Humacyte reiterated their overweight rating.

Q

When is the next analyst rating going to be posted or updated for Humacyte (HUMA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Humacyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Humacyte was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.

Q

Is the Analyst Rating Humacyte (HUMA) correct?

A

While ratings are subjective and will change, the latest Humacyte (HUMA) rating was a reiterated with a price target of $0.00 to $7.00. The current price Humacyte (HUMA) is trading at is $2.88, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Humacyte Stock (NASDAQ:HUMA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Outperform

Highest Price Target1

$17.00

Lowest Price Target1

$7.00

Consensus Price Target1

$13.83

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
42000

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Benchmark
  • BTIG
  • Cowen & Co.
  • Oppenheimer

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Humacyte

All Ratings (12)

Upgrades (0)

Downgrades (0)

Initiations (5)

Q

What is the target price for Humacyte (HUMA)?

A

The latest price target for Humacyte (NASDAQ: HUMA) was reported by Cantor Fitzgerald on September 21, 2023. The analyst firm set a price target for $7.00 expecting HUMA to rise to within 12 months (a possible 143.06% upside). 7 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Humacyte (HUMA)?

A

The latest analyst rating for Humacyte (NASDAQ: HUMA) was provided by Cantor Fitzgerald, and Humacyte reiterated their overweight rating.

Q

When is the next analyst rating going to be posted or updated for Humacyte (HUMA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Humacyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Humacyte was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.

Q

Is the Analyst Rating Humacyte (HUMA) correct?

A

While ratings are subjective and will change, the latest Humacyte (HUMA) rating was a reiterated with a price target of $0.00 to $7.00. The current price Humacyte (HUMA) is trading at is $2.88, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Humacyte Stock (NASDAQ:HUMA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Outperform

Highest Price Target1

$17.00

Lowest Price Target1

$7.00

Consensus Price Target1

$13.83

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
42000

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Benchmark
  • BTIG
  • Cowen & Co.
  • Oppenheimer

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Humacyte

All Ratings (12)

Upgrades (0)

Downgrades (0)

Initiations (5)

Q

What is the target price for Humacyte (HUMA)?

A

The latest price target for Humacyte (NASDAQ: HUMA) was reported by Cantor Fitzgerald on September 21, 2023. The analyst firm set a price target for $7.00 expecting HUMA to rise to within 12 months (a possible 143.06% upside). 7 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Humacyte (HUMA)?

A

The latest analyst rating for Humacyte (NASDAQ: HUMA) was provided by Cantor Fitzgerald, and Humacyte reiterated their overweight rating.

Q

When is the next analyst rating going to be posted or updated for Humacyte (HUMA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Humacyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Humacyte was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.

Q

Is the Analyst Rating Humacyte (HUMA) correct?

A

While ratings are subjective and will change, the latest Humacyte (HUMA) rating was a reiterated with a price target of $0.00 to $7.00. The current price Humacyte (HUMA) is trading at is $2.88, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Humacyte Stock (NASDAQ:HUMA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Outperform

Highest Price Target1

$17.00

Lowest Price Target1

$7.00

Consensus Price Target1

$13.83

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
42000

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Benchmark
  • BTIG
  • Cowen & Co.
  • Oppenheimer

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Humacyte

All Ratings (12)

Upgrades (0)

Downgrades (0)

Initiations (5)

Q

What is the target price for Humacyte (HUMA)?

A

The latest price target for Humacyte (NASDAQ: HUMA) was reported by Cantor Fitzgerald on September 21, 2023. The analyst firm set a price target for $7.00 expecting HUMA to rise to within 12 months (a possible 143.06% upside). 7 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Humacyte (HUMA)?

A

The latest analyst rating for Humacyte (NASDAQ: HUMA) was provided by Cantor Fitzgerald, and Humacyte reiterated their overweight rating.

Q

When is the next analyst rating going to be posted or updated for Humacyte (HUMA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Humacyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Humacyte was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.

Q

Is the Analyst Rating Humacyte (HUMA) correct?

A

While ratings are subjective and will change, the latest Humacyte (HUMA) rating was a reiterated with a price target of $0.00 to $7.00. The current price Humacyte (HUMA) is trading at is $2.88, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Humacyte Stock (NASDAQ:HUMA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Outperform

Highest Price Target1

$17.00

Lowest Price Target1

$7.00

Consensus Price Target1

$13.83

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
42000

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Benchmark
  • BTIG
  • Cowen & Co.
  • Oppenheimer

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Humacyte

All Ratings (12)

Upgrades (0)

Downgrades (0)

Initiations (5)

Q

What is the target price for Humacyte (HUMA)?

A

The latest price target for Humacyte (NASDAQ: HUMA) was reported by Cantor Fitzgerald on September 21, 2023. The analyst firm set a price target for $7.00 expecting HUMA to rise to within 12 months (a possible 143.06% upside). 7 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Humacyte (HUMA)?

A

The latest analyst rating for Humacyte (NASDAQ: HUMA) was provided by Cantor Fitzgerald, and Humacyte reiterated their overweight rating.

Q

When is the next analyst rating going to be posted or updated for Humacyte (HUMA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Humacyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Humacyte was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.

Q

Is the Analyst Rating Humacyte (HUMA) correct?

A

While ratings are subjective and will change, the latest Humacyte (HUMA) rating was a reiterated with a price target of $0.00 to $7.00. The current price Humacyte (HUMA) is trading at is $2.88, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Humacyte Stock (NASDAQ:HUMA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Outperform

Highest Price Target1

$17.00

Lowest Price Target1

$7.00

Consensus Price Target1

$13.83

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
42000

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Benchmark
  • BTIG
  • Cowen & Co.
  • Oppenheimer

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Humacyte

All Ratings (12)

Upgrades (0)

Downgrades (0)

Initiations (5)

Q

What is the target price for Humacyte (HUMA)?

A

The latest price target for Humacyte (NASDAQ: HUMA) was reported by Cantor Fitzgerald on September 21, 2023. The analyst firm set a price target for $7.00 expecting HUMA to rise to within 12 months (a possible 143.06% upside). 7 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Humacyte (HUMA)?

A

The latest analyst rating for Humacyte (NASDAQ: HUMA) was provided by Cantor Fitzgerald, and Humacyte reiterated their overweight rating.

Q

When is the next analyst rating going to be posted or updated for Humacyte (HUMA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Humacyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Humacyte was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.

Q

Is the Analyst Rating Humacyte (HUMA) correct?

A

While ratings are subjective and will change, the latest Humacyte (HUMA) rating was a reiterated with a price target of $0.00 to $7.00. The current price Humacyte (HUMA) is trading at is $2.88, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Humacyte Stock (NASDAQ:HUMA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Outperform

Highest Price Target1

$17.00

Lowest Price Target1

$7.00

Consensus Price Target1

$13.83

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
42000

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Benchmark
  • BTIG
  • Cowen & Co.
  • Oppenheimer

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Humacyte

All Ratings (12)

Upgrades (0)

Downgrades (0)

Initiations (5)

Q

What is the target price for Humacyte (HUMA)?

A

The latest price target for Humacyte (NASDAQ: HUMA) was reported by Cantor Fitzgerald on September 21, 2023. The analyst firm set a price target for $7.00 expecting HUMA to rise to within 12 months (a possible 143.06% upside). 7 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Humacyte (HUMA)?

A

The latest analyst rating for Humacyte (NASDAQ: HUMA) was provided by Cantor Fitzgerald, and Humacyte reiterated their overweight rating.

Q

When is the next analyst rating going to be posted or updated for Humacyte (HUMA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Humacyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Humacyte was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.

Q

Is the Analyst Rating Humacyte (HUMA) correct?

A

While ratings are subjective and will change, the latest Humacyte (HUMA) rating was a reiterated with a price target of $0.00 to $7.00. The current price Humacyte (HUMA) is trading at is $2.88, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Humacyte Stock (NASDAQ:HUMA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Outperform

Highest Price Target1

$17.00

Lowest Price Target1

$7.00

Consensus Price Target1

$13.83

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
42000

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Benchmark
  • BTIG
  • Cowen & Co.
  • Oppenheimer

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Humacyte

All Ratings (12)

Upgrades (0)

Downgrades (0)

Initiations (5)

Q

What is the target price for Humacyte (HUMA)?

A

The latest price target for Humacyte (NASDAQ: HUMA) was reported by Cantor Fitzgerald on September 21, 2023. The analyst firm set a price target for $7.00 expecting HUMA to rise to within 12 months (a possible 143.06% upside). 7 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Humacyte (HUMA)?

A

The latest analyst rating for Humacyte (NASDAQ: HUMA) was provided by Cantor Fitzgerald, and Humacyte reiterated their overweight rating.

Q

When is the next analyst rating going to be posted or updated for Humacyte (HUMA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Humacyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Humacyte was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.

Q

Is the Analyst Rating Humacyte (HUMA) correct?

A

While ratings are subjective and will change, the latest Humacyte (HUMA) rating was a reiterated with a price target of $0.00 to $7.00. The current price Humacyte (HUMA) is trading at is $2.88, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Humacyte Stock (NASDAQ:HUMA), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Outperform

Highest Price Target1

$17.00

Lowest Price Target1

$7.00

Consensus Price Target1

$13.83

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
42000

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Benchmark
  • BTIG
  • Cowen & Co.
  • Oppenheimer

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Humacyte

All Ratings (12)

Upgrades (0)

Downgrades (0)

Initiations (5)

Q

What is the target price for Humacyte (HUMA)?

A

The latest price target for Humacyte (NASDAQ: HUMA) was reported by Cantor Fitzgerald on September 21, 2023. The analyst firm set a price target for $7.00 expecting HUMA to rise to within 12 months (a possible 143.06% upside). 7 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Humacyte (HUMA)?

A

The latest analyst rating for Humacyte (NASDAQ: HUMA) was provided by Cantor Fitzgerald, and Humacyte reiterated their overweight rating.

Q

When is the next analyst rating going to be posted or updated for Humacyte (HUMA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Humacyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Humacyte was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.

Q

Is the Analyst Rating Humacyte (HUMA) correct?

A

While ratings are subjective and will change, the latest Humacyte (HUMA) rating was a reiterated with a price target of $0.00 to $7.00. The current price Humacyte (HUMA) is trading at is $2.88, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.